AR039210A1 - Panel de diagnostico del cancer - Google Patents

Panel de diagnostico del cancer

Info

Publication number
AR039210A1
AR039210A1 ARP030101131A ARP030101131A AR039210A1 AR 039210 A1 AR039210 A1 AR 039210A1 AR P030101131 A ARP030101131 A AR P030101131A AR P030101131 A ARP030101131 A AR P030101131A AR 039210 A1 AR039210 A1 AR 039210A1
Authority
AR
Argentina
Prior art keywords
cancer diagnostic
diagnostic panel
genes
gene
expression
Prior art date
Application number
ARP030101131A
Other languages
English (en)
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of AR039210A1 publication Critical patent/AR039210A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Un método para diagnostico del cáncer a través de la identificación de la modulación diferencial de cada gen (relativo a la expresión de los mismos genes en una población normal) en una combinación de genes seleccionados de dos grupos de genes. Los porfolios de expresión génica y kits para emplear el método son aspectos adicionales de la invención.
ARP030101131A 2002-03-29 2003-04-01 Panel de diagnostico del cancer AR039210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36866702P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
AR039210A1 true AR039210A1 (es) 2005-02-09

Family

ID=28675523

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101131A AR039210A1 (es) 2002-03-29 2003-04-01 Panel de diagnostico del cancer

Country Status (10)

Country Link
US (2) US7348142B2 (es)
EP (1) EP1355150A3 (es)
JP (2) JP4409845B2 (es)
KR (1) KR20030078799A (es)
CN (2) CN100577813C (es)
AR (1) AR039210A1 (es)
AU (1) AU2003203553A1 (es)
BR (1) BR0303011A (es)
CA (1) CA2422319A1 (es)
MX (1) MXPA03002862A (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551778B1 (en) * 1999-01-28 2003-04-22 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US7348142B2 (en) * 2002-03-29 2008-03-25 Veridex, Lcc Cancer diagnostic panel
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20080228405A1 (en) * 2005-08-05 2008-09-18 Koninklijke Philips Electronics, N.V. Search Space Coverage With Dynamic Gene Distribution
JP2009508493A (ja) * 2005-09-19 2009-03-05 ベリデックス・エルエルシー すい臓がんを診断するための方法
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
CA2636855C (en) 2006-01-11 2016-09-27 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
EP1996729A2 (en) * 2006-03-03 2008-12-03 Veridex, LLC Molecular assay to predict recurrence of dukes' b colon cancer
EP3031918B1 (en) 2006-05-11 2018-03-14 Raindance Technologies Inc. Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008073578A2 (en) * 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP2315629B1 (en) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Droplet libraries
WO2010033294A1 (en) * 2008-09-22 2010-03-25 Cedars-Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
DK3508589T3 (da) * 2010-09-13 2023-06-06 Clinical Genomics Pty Ltd Epigenetiske markører af kolorektale kræftformer og diagnostiske fremgangsmåder under anvendelse af det samme
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
EP2673614B1 (en) 2011-02-11 2018-08-01 Raindance Technologies, Inc. Method for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP2714970B1 (en) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP3524693A1 (en) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digital analyte analysis
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
WO2014205266A2 (en) * 2013-06-20 2014-12-24 The Broad Institute Compositions and methods for detecting and treating glioblastoma
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN106086220A (zh) * 2016-08-19 2016-11-09 浙江省中医院 一种非小细胞肺癌单核苷酸多态性检测试剂盒及其应用
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
WO2019144275A1 (zh) * 2018-01-23 2019-08-01 北京艾克伦医疗科技有限公司 鉴定肺癌状态的方法和试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6350576B1 (en) 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
US5695937A (en) * 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US6275814B1 (en) 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
EP1163524A2 (en) 1999-03-15 2001-12-19 EOS Biotechnology, Inc. Methods of screening for colorectal cancer modulators
US6175824B1 (en) 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
RU2251838C2 (ru) 1999-07-15 2005-05-20 Рисерч Дивелопмент Фаундейшн Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование
US6221600B1 (en) * 1999-10-08 2001-04-24 Board Of Regents, The University Of Texas System Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis
WO2002024956A2 (en) * 2000-09-19 2002-03-28 Whitehead Institute For Biomedical Research Genetic markers for tumors
CA2439074A1 (en) * 2001-03-09 2002-09-19 Nugen Technologies, Inc. Methods and compositions for amplification of rna sequences
CA2450379A1 (en) * 2001-06-10 2002-12-19 Irm Llc Molecular signatures of commonly fatal carcinomas
US7348142B2 (en) * 2002-03-29 2008-03-25 Veridex, Lcc Cancer diagnostic panel

Also Published As

Publication number Publication date
JP4409845B2 (ja) 2010-02-03
MXPA03002862A (es) 2004-08-11
JP2009118855A (ja) 2009-06-04
JP2004033215A (ja) 2004-02-05
AU2003203553A1 (en) 2003-10-23
US7348142B2 (en) 2008-03-25
CA2422319A1 (en) 2003-09-29
CN1495275A (zh) 2004-05-12
EP1355150A3 (en) 2004-08-25
EP1355150A2 (en) 2003-10-22
BR0303011A (pt) 2004-02-17
US20090221445A1 (en) 2009-09-03
CN100577813C (zh) 2010-01-06
US20030194733A1 (en) 2003-10-16
KR20030078799A (ko) 2003-10-08
CN101705291A (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
AR039210A1 (es) Panel de diagnostico del cancer
AR043808A1 (es) Pronostico de cancer colorrectal
Khan et al. Defining cancer survivorship: a more transparent approach is needed
Li et al. Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway
WO2001094629A3 (en) Cancer gene determination and therapeutic screening using signature gene sets
TW200600785A (en) Method for diagnosing non-small cell lung cancer
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
ATE424560T1 (de) Marker für neuromyelitis optica
ES2111289T3 (es) Metodos y kits de diagnostico que emplean promotores de estres en mamiferos para determinar la toxicidad de un compuesto.
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
NO20002979D0 (no) Undersøkelse av human papillomavirus-relatert sykdom
BRPI0410634A (pt) processo
WO2006042328A3 (en) Treatment of cancer and compositions
Sarungbam et al. Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile
AR039213A1 (es) Porfolio de pronostico del cancer de mamas
EP1492440A4 (en) NEW PROCEDURE FOR THE DIAGNOSIS AND FORECAST OF MALIGNES DISEASES
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
AR044099A1 (es) Pronostico de cancer de mama
CY1116133T1 (el) Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης
BRPI0512081A (pt) azaporfirinas substituìdas como rótulos de fluorescência
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
CR9298A (es) Marcadores farmacogenomicos para el pronostico de tumores solidos
WO2008037700A3 (en) Methods for breast cancer prognosis
WO2005118865A3 (en) Diagnosis and treatment of drug resistant leukemia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal